Viking Therapeutics, Inc. $VKTX Shares Sold by Signaturefd LLC

Signaturefd LLC decreased its position in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 41.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,671 shares of the biotechnology company’s stock after selling 1,159 shares during the quarter. Signaturefd LLC’s holdings in Viking Therapeutics were worth $44,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. Lewis Asset Management LLC raised its holdings in Viking Therapeutics by 0.9% in the second quarter. Lewis Asset Management LLC now owns 44,060 shares of the biotechnology company’s stock valued at $1,168,000 after acquiring an additional 385 shares in the last quarter. HighMark Wealth Management LLC grew its position in shares of Viking Therapeutics by 9.4% in the 1st quarter. HighMark Wealth Management LLC now owns 4,660 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 400 shares during the last quarter. Xponance Inc. grew its position in shares of Viking Therapeutics by 3.2% in the 1st quarter. Xponance Inc. now owns 14,470 shares of the biotechnology company’s stock valued at $349,000 after buying an additional 446 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Viking Therapeutics by 33.4% in the 2nd quarter. Parallel Advisors LLC now owns 1,818 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 455 shares during the last quarter. Finally, Deutsche Bank AG grew its position in shares of Viking Therapeutics by 7.5% in the 1st quarter. Deutsche Bank AG now owns 6,911 shares of the biotechnology company’s stock valued at $167,000 after buying an additional 484 shares during the last quarter. Institutional investors and hedge funds own 76.03% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on VKTX shares. HC Wainwright reaffirmed a “buy” rating and issued a $102.00 target price on shares of Viking Therapeutics in a research report on Monday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Saturday, September 27th. Raymond James Financial dropped their target price on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating on the stock in a research report on Thursday, July 24th. Citigroup increased their target price on shares of Viking Therapeutics from $31.00 to $38.00 and gave the company a “neutral” rating in a research report on Thursday, July 24th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $125.00 target price on shares of Viking Therapeutics in a research report on Monday, September 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $86.42.

Viking Therapeutics Stock Performance

Shares of VKTX opened at $32.28 on Tuesday. The stock has a market capitalization of $3.63 billion, a P/E ratio of -21.10 and a beta of 0.64. The company’s fifty day moving average is $29.28 and its two-hundred day moving average is $27.93. Viking Therapeutics, Inc. has a 1 year low of $18.92 and a 1 year high of $81.73.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings data on Wednesday, July 23rd. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.44) by ($0.14). Viking Therapeutics’s quarterly revenue was up NaN% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.20) EPS. Sell-side analysts predict that Viking Therapeutics, Inc. will post -1.56 EPS for the current year.

Viking Therapeutics Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.